The decision positions LANGLARA as only the fourth insulin glargine product available in the US market, joining established products commercialized by Novo Nordisk, Sanofi and Eli Lilly.
Sunshine Lake Pharma breaks US barriers with historic FDA approval for LANGLARA
Healthcaremea
